Our Board

Mr Paul Jeans


Paul Jeans has been Chancellor of The University of Newcastle for over a decade until his retirement in December 2023. In an extensive executive career with BHP, spanning more that 42 years, Paul held many senior executive roles including EGM / CEO of Ferrous Minerals Business and three of its steel businesses, which included responsibility for both Newcastle and Port Kembla steelworks. His earlier career focused on engineering, and he rose to become General Manager of BHP Engineering. Paul has led manufacturing, mining, logistics and technical services businesses through periods of growth, significant change and efficiency improvement, major capital expansion and international operation. He has been chair of the Newcastle Port Corporation, Orinoco Iron CA, Associated Airlines, World Marine and General Insurances and six BHP subsidiary companies. Paul has also been a Director of Foster’s Brewing Group, Energy Australia and Ausgrid.

Professor David Thomas

Chief Science and Strategy Officer

Prof David Thomas is the founder and Chief Science and Strategy Officer of Omico. An NHMRC L3 Investigator, he is also the inaugural Director of the Centre for Molecular Oncology at the University of New South Wales, and Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research. As a clinician-scientist, his focus is on the application of genomic technologies to the understanding and management of cancer, particularly sarcoma. In 2019, David established Omico, which has brought together researchers and clinicians to translate research into new therapeutic options for patients with cancer. He also founded the Australasian Sarcoma Study Group, a national research organisation, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. Prof Thomas leads the International Sarcoma Kindred Study, now recruiting from 23 centres in 7 countries, and led the first international study of denosumab in Giant Cell Tumour of bone, leading to FDA and TGA approval. He has over 260 research publications, including lead or senior author papers in Science, Cancer Cell, Molecular Cell, Journal of Clinical Investigation, Lancet Oncology, JAMA Oncology, and Journal of Clinical Oncology. In 2018, he was President of the Connective Tissue Oncology Society, the peak international body in his field.

Ian Black

Chief Executive Officer and Director

Ian is a dynamic and motivated healthcare professional with more than 30 years’ experience in the pharmaceutical industry across Australia and New Zealand.  For more than 12 years Ian has held senior leadership roles, including two years as General Manager for Roche Pharmaceuticals in New Zealand. In 2012 Ian founded the Oncology Industry Taskforce, and continued to co-chair this Medicines Australia group until 2016.  Ian is also a Graduate of the Australian Institute of Company Directors (AICD).

Ms. Sue MacLeman


Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has served as CEO and Board member of several ASX, AIM  and NASDAQ listed companies in the healthtech sector. She is currently Non Executive Director at Rhythm Biosciences Ltd, Planet Innovation Holdings, Australian Academy of Technology and Engineering (ATSE)  and Omico. Sue is also appointed to several industry, academic and government advisory boards .Her broad commercial and technical experience is underpinned by a Bachelor of Pharmacy from the University of Queensland, a Master of Laws from Deakin University and a Master of Marketing from Melbourne Business School. She ­is also a Fellow of ATSE and Fellow/Graduate of Australian Institute of Company Directors (AICD).



Professor Benjamin Kile


Executive Director of the Garvan Institute of Medical Research, Professor Benjamin Kile is an internationally recognised medical researcher who has made contributions to the understanding of cancer, stem cells and inflammatory disease. His work has shed light on the mechanisms of programmed cell death, informing the development of the BH3 mimetics, a new class of cancer drugs approved by the FDA in 2016. Prof Kile has a distinguished research leadership background, having occupied senior roles at the Walter and Eliza Hall Institute, Monash University, and the University of Adelaide. He made foundational contributions to the establishment of the National Drug Discovery Centre, the South Australian immunoGENomics Cancer Institute, and the Bragg Comprehensive Cancer Centre.

Mr Bruce Goodwin


Medicines Australia representative – Managing Director, Janssen Australia and New Zealand, Bruce Goodwin’s career with the Johnson & Johnson family of companies spans 35 years. He has been in general management roles for the last ten years including two terms in his current role of Managing Director Janssen Australia and New Zealand, and three years as President and Representative Director of Janssen Japan. Prior to general management, he’s held management board director positions in sales, marketing and in finance, as well as having gained valuable experience in global licensing and acquisitions. His service with Johnson & Johnson outside of his home country, Australia, includes postings to Janssen Japan, Janssen Belgium and Janssen United Kingdom. Bruce is a respected industry leader and is currently an elected director and board member of Medicines Australia, a role he has also held previously. While in Japan, he served as vice-chair of the Japan bBased Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA). Bruce has a strong track record in advocating for policies that support timely and affordable access to innovative medicines and in 2017, he was a key member of the Cancer Drugs Access Committee. Bruce holds an economics degree from Macquarie University and an MBA from Macquarie Graduate School of Management, and is a graduate member of the Australian Institute of Company Directors (GAICD).

Professor John Simes


University of Sydney representative – Senior Associate Director, NHMRC Clinical Trials Centre, University of Sydney. Medical Oncologist, Chris O’Brien Lifehouse and Royal Prince Alfred Hospital. Professor Simes AO, is a leading international researcher in clinical trials, particularly in cancer, cardiovascular disease, diabetes and neonatal medicine. In his position as Senior Associate Director of the NHMRC CTC, he co-leads a broad program of clinical trials research aimed at improving health practice and outcomes globally. His work has had a significant impact on current knowledge and clinical practice. He also practices as a medical oncologist in neuro-oncology. He has published over 430 papers with 85,000 citations. Professor Simes has received an Order of Australia award (AO) for his service to education and medicine in cancer research and clinical trials.

Professor Michael P. Brown


Member representative – Central Adelaide Local Health Network, South Australia – Professor Brown is a director of the Cancer Clinical Trials Unit at Royal Adelaide Hospital. He heads its melanoma research program and chairs its fortnightly melanoma multidisciplinary meeting. He is a senior consultant medical oncologist in the Royal Adelaide Hospital Cancer Centre. Professor Brown sub-specialises in the care of patients with advanced melanoma or lung cancer. His clinical research is focused mainly on facilitating rapid access to new targeted therapies and on early-phase clinical trials testing new immunotherapies for the treatment of melanoma and lung cancer. His laboratory research is focused mainly on understanding better how to direct T cells toward cancer targets. Professor Brown has published 119 papers, including 17 in high impact journals (Lancet, Lancet Oncology, Nature Medicine, Cell, Blood, Clin Cancer Res, Oncogene, Ann Oncology, J Nucl Med) and has an H-index of 30.

Professor Ricky Johnstone


Member representative – Professor Johnstone is a cancer researcher who has utilised genetic mouse models of haemopoietic malignancies and solid tumours to understand the epigenetic changes that underpin tumour onset and progression, and to develop new therapies that target epigenetic and transcriptional regulatory proteins. Professor Johnstone has recently discovered how epigenetic-based agents can engage the host immune system to drive prolonged therapeutic responses. Professor Johnstone and his team are advancing these fundamental discoveries through the implementation of clinical trials that combine epigenetic and immunotherapeutic agents. Professor Johnstone has published a total of 227 papers with >25,000 total citations, and he has an H-index of 74.

Ms. Tze Masters


Tze is a high impact business leader with strong strategic skills, financial and investment capabilities. Tze has over twenty years experience in the investment, finance and banking sectors, coupled with a high level of general management, entrepreneurial and communication skills.

Dr Anna Lavelle

Medicines Australia Nominee Director

Dr Anna Lavelle AM is an experienced Non – Executive Director serving for over 28 years on the boards of not for profit, government and for profit entities.  As Executive Director or Non Executive Director she has a deep and lengthy track record in healthcare delivery, technology development, negotiating policy/legislative outcomes and governance. Anna has a PhD in Genetics from the University of Melbourne and is a Graduate of the Australian Institute of Company Directors (GAICD).  Anna is a Fellow of the Academy of Technology Science and Engineering (FTSE) and is also a Fellow of the Leadership Victoria Program.  In 2015 Nature Scientific America, World View ranked Anna in the global top 100 “World Visionaries” in biotechnology.  Anna was the only Australian to be named. In 2023 Anna was awarded an AM and admitted to the Order of Australia for services to innovation and science. From 2005 to 2016, Anna was the CEO of AusBiotech; the national industry association for the biotechnology, pharmaceutical and medical devices sectors.

A/Professor Paul Martin

Company Secretary

Paul is an associate professor at the University of Sydney and lectures in banking and risk management. He is also currently the company secretary of both Intersect Australia Limited and the Sydney School of Entrepreneurship Limited. Paul has over twenty years’ experience in the banking industry, having worked for a number of banking organisations including Advance Bank of Australia, the Australian Financial Markets Association, Hong Kong Bank of Australia Limited (HSBC), Australian Bank Limited and the Commonwealth Banking Corporation. He was previously the chief financial officer and company secretary of the Securities Industry Research Centre of Asia-Pacific (SIRCA), and was responsible for all aspects of the company’s management and operating functions including liaison with SIRCA’s key industry partners the ASX, the Sydney Futures Exchange, the Australian Financial Markets Association and Thomson Reuters.

Interested in knowing more?

Get in touch